Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
Coordination Pharmaceuticals, Inc.
Basilea Pharmaceutica
OX2 Therapeutics
Adaptimmune
Pfizer
EpicentRx, Inc.
Boston Scientific Corporation
Cavion
Oncolys BioPharma Inc
AbbVie
Sanofi
AstraZeneca